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JMJD5 is a human arginyl C-3 hydroxylase
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Oxygenase-catalysed post-translational modifications of basic protein residues, including
lysyl hydroxylations and Nε-methyl lysyl demethylations, have important cellular roles.
Jumonji-C (JmjC) domain-containing protein 5 (JMJD5), which genetic studies reveal is
essential in animal development, is reported as a histone Nε-methyl lysine demethylase
(KDM). Here we report how extensive screening with peptides based on JMJD5 interacting
proteins led to the finding that JMJD5 catalyses stereoselective C-3 hydroxylation of arginine
residues in sequences from human regulator of chromosome condensation domain-
containing protein 1 (RCCD1) and ribosomal protein S6 (RPS6). High-resolution crystal-
lographic analyses reveal overall fold, active site and substrate binding/product release
features supporting the assignment of JMJD5 as an arginine hydroxylase rather than a KDM.
The results will be useful in the development of selective oxygenase inhibitors for the
treatment of cancer and genetic diseases.
Corrected: Publisher correction
DOI: 10.1038/s41467-018-03410-w OPEN
1 The Department of Chemistry, University of Oxford, Mansfield Road, Oxford OX1 3TA, UK. 2Present address: Leicester Institute of Structural and Chemical
Biology and Department of Chemistry, University of Leicester, Lancaster Road, Leicester LE1 7RH, UK. 3Present address: Stanford University School of
Medicine, Department of Molecular and Cellular Physiology, Clark Center, Stanford, CA 94305-5345, USA. Correspondence and requests for materials
should be addressed to C.J.S. (email: christopher.schofield@chem.ox.ac.uk) or to R.C. (email: rashed.chowdhury@stanford.edu)









The Jumonji-C (JmjC) family of Fe(II) and 2-oxoglutarate(2OG) dependent oxygenases play important roles in theregulation of protein biosynthesis1,2. In eukaryotes, the
JmjC histone demethylases (KDMs) catalyse Nε-methyl lysine-
and, possibly, N-methyl arginine-residue demethylation of his-
tones3,4. Unlike the flavin-dependent lysine-specific histone
demethylases (LSDs), the JmjC KDMs catalyse the demethylation
of all Nε-methyl lysine methylation states and are important
regulators of transcription5,6. Although the effects of genetic or
small-molecule intervention of the JmjC KDMs at the cellular
level are often subtle, mutations to these enzymes are linked to
multiple diseases, and some JmjC KDMs are current medicinal
chemistry targets7–9.
A second group of JmjC enzymes (hydroxylases) do not have
KDM activity, instead they catalyse the formation of stable
alcohol products arising from the oxidation of protein residues1.
FIH (factor-inhibiting hypoxia-inducible factor/HIF), the first
JmjC enzyme to be identified, regulates the hypoxic response via
C-3 hydroxylation of an Asn-residue, a post-translational mod-
ification (PTM) blocking the interaction between HIF and the
CBP/p300 transcriptional coactivators1,2. FIH also catalyses Asn-,
Asp- and His-residue hydroxylation in multiple ankyrin repeat
domain (ARD) proteins1,2. JMJD6 catalyses Lys-residue C-5
hydroxylation of splicing regulatory proteins and, possibly, N,N-
dimethyl Arg-demethylation, though the latter is controversial10.
JMJD4 catalyses Lys-hydroxylation, but at C-4 on eukaryotic
release factor 1, a modification that promotes translation termi-
nation efficiency1,2. The ribosomal oxygenases (RIOX) catalyse
the modification of ribosomal proteins; in prokaryotes, ycfD
catalyses the C-3 hydroxylation of an Arg-residue in ribosomal
protein L16; its human homologues MINA53 and NO66 catalyse
C-3 hydroxylation of His-residues in rpl27a and rpL8,
respectively1,2.
JMJD5 is a JmjC domain-containing protein, present in both
the nucleus and the cytoplasm11,12. Genetic studies reveal that
deletion of JMJD5 has profound detrimental effects, including
embryonic lethality13,14. JMJD5 has many important biological
roles, including regulation of cell cycle and pluripotency (via
regulating cyclin-dependent kinase inhibitor 1 (CDKN1A)
levels15,16), p53 signalling and mitosis (via association with
spindle microtubules17,18), glucose metabolism and chromosome
stability (via interactions with pyruvate kinase M2/PKM219 and
RCCD120), and osteoclast differentiation (by destabilising nuclear
factor of activated T-cells, cytoplasmic 1 (NFATC1)21). JMJD5 is
identified being as pro-oncogenic, in colon22 and breast23 cancer.
Despite its important biological roles, the biochemical function
of JMJD5 has been elusive. Early studies identified JMJD5 as a
histone H3K36me2 demethylase regulating cyclin A1 expres-
sion11; however, this assignment has not been validated subse-
quently21,24,25. Recently, evidence has been reported that JMJD5
has aminopeptidase activity on histone tails26,27. Thus, JMJD5 is
one of the few human JmjC oxygenases for which a clear bio-
chemical function has not been defined. Given the evidence for
the biological importance of JMJD5, which is unusually clear
compared to most other JmjC proteins, and that other (related)
JmjC enzymes are being pursued as pharmaceutical targets, it is
important to assign the catalytic role of JMJD5. Here we report
evidence that JMJD5 is a JmjC arginyl-hydroxylase, the first such
catalytic activity identified for a human enzyme.
Results
JMJD5 catalyses C-3 arginyl hydroxylation. We began by ana-
lysing whether JMJD5 can convert 2OG into succinate without
substrate, as observed for many 2OG-oxygenases. By 1H-NMR,
we observed low levels of JMJD5/Fe(II)-dependent 2OG to
succinate conversion, which was inhibited by the broad-spectrum
2OG-oxygenase inhibitor N-oxalylglycine (NOG) (Fig. 1). Sub-
stitution of one of the Fe(II)-binding residues (H321, as crystal-
lographically observed in JMJD5 structures without substrate)
24,25 with alanine significantly reduced 2OG turnover (Fig. 1).
These results support the assignment of JMJD5 as a functional
2OG-oxygenase.
Bioinformatic and structural analyses suggest JMJD5 is more
closely related to the JmjC-hydroxylases than JmjC KDMs
(Supplementary Fig. 1)1,24,25. However, because JMJD5 has been
assigned as a KDM11, we investigated both hydroxylase and KDM
activities for recombinant JMJD5 using reported substrate(s) and
binding proteins—H3K36me2 (for demethylation activity)11,28
and p5317, NFATC121, PKM219 and RCCD120 (for hydroxylation
activity).
To investigate KDM activity for JMJD5, we employed a mass
spectrometry (MS)-based assay, using conditions enabling
demethylation of histone Nε-methylated lysine residues by other
KDMs29. We tested synthetic histone H3 fragment peptides (21-
mers) containing all three methylation states (Kme3/Kme2/Kme1)
at K4, K9, K27 and K36 sites, but observed no evidence for
demethylation (or other modifications), including with the
reported H3K36me2 substrate11 (Supplementary Fig. 2). In
addition to wild type, an N-terminally truncated JMJD5 (aa
183–416) was tested because the JMJD5 N-terminus (aa 1–182) is
reported to constitute an 'inhibitory domain' that might block its
demethylase activity24. The truncated JMJD5, however, also did
not manifest KDM activity.
We therefore investigated whether JMJD5 has any hydroxylase
activity by synthesising peptides spanning all residues in the
reported JMJD5 interacting proteins (p5317,18, NFATC121,
PKM219 and RCCD120) and testing them using MS assays. The
results reveal a JMJD5-dependent shift of +16 Da on a single
peptide comprising residues 134–150 of human RCCD1, which
was abrogated by alanine substitution of the arginine at position
141 in RCCD1 (Supplementary Fig. 3 and Supplementary
Table 1). This observation suggested the possibility of JMJD5-
catalysed arginyl-hydroxylation, which is notable, because to date
there has been no report of an arginyl-hydroxylase in humans, or
indeed eukaryotes. This finding motivated the investigations of
further JMJD5-catalysed hydroxylations.
JMJD5 catalyses RPS6 arginyl hydroxylation. Recent work has
revealed roles for structurally related JmjC-hydroxylases in reg-
ulating protein synthesis, via post-translational hydroxylations of
ribosomal and associated proteins1,2. We therefore considered
that JMJD5 might catalyse hydroxylation of proteins involved in
translation. We screened ∼1000 peptides derived from human
ribosomal proteins (Supplementary Data 1) using an MS-based
assay, and identified a peptide derived from the 40S ribosomal
protein S6 (RPS6) that showed a mass shift of +16 Da following
incubation with JMJD5, Fe(II), 2OG and ascorbate, consistent
with a single hydroxylation (Fig. 1). This shift was not observed in
the absence of supplemented Fe(II) or 2OG, and was inhibited by
addition of NOG (Supplementary Fig. 4).
Alanine scanning and tandem mass spectrometric (MS/MS)
analysis of the modified peptide revealed that the hydroxylated
residue is likely an arginine, corresponding to R137 in human
RPS6 (Fig. 1, Supplementary Fig. 5 and Supplementary Table 3).
The activity of JMJD5 is apparently specific to arginine residues,
as substitution of the target arginine with other residues,
including lysine, did not enable hydroxylation (Supplementary
Fig. 6). JMJD5 did not catalyse hydroxylation/demethylation of
an Nε-dimethyl lysine residue at this position, nor was it able to
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Fig. 1 JMJD5 catalyses stereoselective C-3 hydroxylation of Arg137 of the 40S ribosomal protein S6 (RPS6). a MALDI-MS spectra for RPS6129–144 showing
the +16m/z shift following treatment with JMJD5 and cofactors. b MS/MS analysis of the modified RPS6129–144 indicating a +16 shift on y and b ion
fragments y8–y14/b9–b15, which is not observed for ion fragments y1–y7/b2–b8, implying hydroxylation at RPS6 R137; observed/predicted masses for the
fragment ions are given in Supplementary Fig. 5. c Plot of succinate formation monitored by 1H-NMR. Succinate formation from a reaction with 10 μM
JMJD5, 50 μM RPS6, 200 μM 2OG and 100 μM Fe(II) (black) is compared to that without RPS6 peptide (blue), with ascorbate (red), and with an inactive
H321A variant substituting for wild type (yellow). Results are the mean ± s.e.m. (n= 3). d JMJD5-catalysed arginyl hydroxylation. e Extracted ion
chromatograms (m/z= 345) from LC-MS analysis of synthetic (3R)- and (3S)-hydroxyarginine (HyR) standards and amino-acid hydrolysates from
unmodified/hydroxylated RPS6129–144. Peaks at 1.93 and 2.02min correspond to (3R)- and (3S)-hydroxyarginine, respectively. f1H–13C HSQC spectra of
hydroxylated RPS6129–144 (VPRRLGPKROHASRIRKL), labelled with aa assignments, supporting R137 C-3 hydroxylation. Red boxes highlight the
hydroxyarginine (ROH). Inset bottom right: 1H–1H COSY spectrum showing the correlation between C-2-ROH and C-3-ROH protons. ♯ Indicates residual
HEPES buffer
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catalyse any modification of mono- or di-methyl arginine
residues (in the context of the RPS6 peptide).
Nuclear magnetic resonance (NMR) spectroscopy and amino-
acid analysis of the modified RPS6 peptide confirmed the
presence of hydroxyarginine and revealed that JMJD5 catalyses
stereoselective formation of the (2S,3R)-arginine stereoisomer
(Fig. 1). The same stereoisomer is produced by the bacterial
arginyl-hydroxylase ycfD on its L16 substrate30,31. However,
JMJD5 and ycfD do not exhibit any cross-reactivity on their
respective ribosomal protein substrates (Supplementary Fig. 7).
We further investigated the substrate preference of JMJD5 by
incubating equimolar amounts of RCCD1 and RPS6 peptides.
The results reveal that, within the context of peptide substrates,
JMJD5 displays a clear preference for hydroxylation of RPS6 over
RCCD1 (Supplementary Fig. 8). Kinetic analyses reveal that
JMJD5 catalyses RPS6 fragment Arg137 hydroxylation with a
several fold lower Km value than for RCCD1 (60.4 µM and >300
µM, respectively) (Supplementary Fig. 8).
Structures imply JMJD5 is an arginyl hydroxylase. Although the
animal JmjC KDMs and hydroxylases likely have common evo-
lutionary origins in prokaryotic oxygenases, structural studies
have revealed emerging fold and active site features characteristic
of the two subfamilies30,32. Although structures of JMJD5 in the
absence of substrate are reported24,25, these do not inform on the
relationship of the Fe-linked reactive intermediate in 2OG-
oxygenase catalysis with the substrate; we therefore initiated
crystallographic studies on JMJD5 substrate complexes with an
aim of investigating the structural basis for its catalytic activity.
In attempts to crystallise JMJD5, including full-length and N-
terminally truncated (aa 153–416 and aa 183–416) constructs, we
obtained diffraction quality crystals with JMJD5153-416 and
JMJD5183-416, with the latter diffracting to substantially higher
resolution (1.1–1.7 Å). We obtained multiple JMJD5 structures in
complex with 2OG or the broad-spectrum inhibitor NOG (IC50 6
± 1.4 µM for JMJD5) in the P3221 (JMJD5153-416) or P212121
(JMJD5183-416) space groups. Consistent with previous
reports24,25, JMJD5 residues 174–416 fold into mixed helical
and β-strand topology comprising seven α-helices, 13 β-strands
and 3 310 helices (Fig. 2a,b). The core architecture is a distorted
double-stranded β-helix (DSBH) fold, an asymmetric barrel-like
structure formed by eight antiparallel β-strands in major (I, VIII,
III, VI) and minor (II, VII, IV, V) sheets, which is archetypical of
2OG-oxygenases33 (DSBH β-strands are in Roman numerals).
Several α- and 310-helices located N-terminal to the DSBH
support the core structure. The active site is located at the
relatively open end of the DSBH barrel; the other end is more
'closed' by the N-terminal β1 (aa 183–188) (Fig. 2a,b).
Like most 2OG-oxygenases, the JMJD5 active site contains a
metal centre, which is octahedrally coordinated by an HXD..H
motif (H321 and D323/βII, H400/βVII), the 2OG oxalyl group
and a water molecule, which is likely replaced by a dioxygen
during catalysis. The 2OG C1-carboxylate also makes hydrogen
bonding interactions with the sidechain –NH2 of N327 (βIII)
(Fig. 2c). Like FIH and other JmjC-hydroxylases33, the 2OG C5-
carboxylate is positioned to form electrostatic interactions with a
lysine (K336) from DSBH βIV and a tyrosine (Y272) from β5,
which is located immediately N-terminal to DSBH βI and which
forms an N-terminal extension to the DSBH major sheet (Fig. 2).
A distinctive feature of 2OG-binding by JMJD5, compared to
most other 2OG-oxygenases33, is that the 2OG C5-carboxylate
interacts with a third polar residue, a serine (S318 from βII). The
two methylenes of 2OG are tightly bound in a hydrophobic
region formed by the sidechains of W310 (βI), L329 (βIII), and
V402 (βVII) (Fig. 2c). Substitution of H321 or W310 by Ala led to
loss of activity (Supplementary Fig. 9). The multiple interactions
between the 2OG and JMJD5 likely reflect tight co-substrate
binding and are consistent with the relatively low Km for 2OG
(9.5 µM) (Supplementary Fig. 8d) and the low level of JMJD5-
catalysed substrate-uncoupled turnover of 2OG (Fig. 1).
Initial attempts to obtain JMJD5.substrate (with both RPS6 and
RCCD1) complex structures yielded a crystal structure of JMJD5.
RPS6 complex (Complex 1) in which difference electron density
(Fo–Fc) was only observed for the RPS6 target arginine near the
active site in two side-chain conformations (A and B, Fig. 3a). In
both conformations (A and B), the nearly overlapped RPS6
argininyl-guanidino group is apparently tightly bound via a salt
bridge with E238 (which is the only acidic residue within 12 Å of
the active site metal) and a cation–π interaction with Y243, which
is located on the β3–β4 loop N-terminal to DSBH (Fig. 3a). In
conformation A, these interactions project the target argininyl C-
3 hydrogens towards the metal (metal–β-CH2, 4.1 Å). By contrast,
in conformation B, the argininyl C-3 is ~9.0 Å away from the
metal centre indicating that in conformation B, the residue is not
positioned in a catalytically productive manner (Fig. 3a).
Consistent with their crystallographically implied importance in
substrate binding, the E238A and Y243A variants were inactive
under standard assay conditions (Supplementary Fig. 9).
The lack of observed difference density (Fo−Fc) for the RPS6
































































































Fig. 2 Overview of the JMJD5 structure. Topology (a) and ribbon representation (b) of the JMJD5.Mn.2OG complex and the active site close-up (c) (PDB:
6F4S). DSBH secondary structure elements are labelled I–VIII (green). The JMJD5 fold contains 7 α-helices, 13 β-strands and 3 310 helices. The N-terminal
domain preceding the DSBH is in orange and the remainder of the structure, including the DSBH βIV–V insert, in light green. 2OG is shown by cyan sticks
and the metal by a purple sphere
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Fig. 3 Stereoviews of JMJD5.substrate complexes showing likely productive and non-productive arginine-binding modes. a JMJD5.Mn.NOG.RPS6
(Complex 1, PDB: 6F4P), b JMJD5(Q275C).Mn.NOG.RPS6(A138C) (Complex 2, PDB: 6F4Q), c JMJD5(N308C).Mn.NOG.RCCD1 (Complex 3, PDB: 6F4R),
d JMJD5(N308C).Mn.2OG.RCCD1 (Complex 4, PDB: 6F4S) and e JMJD5(W414C).Mn.NOG.RCCD1 (Complex 5, PDB: 6F4T). The target arginine in both
RPS6 (R137) and RCCD1 (R141) binds in a shallow channel on the JMJD5 surface forming hydrophobic interactions with Y243/W310 and hydrogen bonds
with E238/ S318 in both 'productive' (Complex 1/A, Complex 3 and Complex 4) and 'non-productive' (Complex 1/B, Complex 2 and Complex 5)
conformations. 2Fo−Fc (grey meshes) for JMJD5 and difference electron density (Fo−FcOMIT map, blue) for substrates are contoured to 1.2−1.5σ and 3σ,
respectively. Red arrows indicate hydroxylated C–H bonds
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an unstable/less stable complex with the RPS6 fragment, possibly
reflecting the relatively high Km value for RPS6 (60.4 μM,
Supplementary Fig. 8e). We therefore pursued a site-specific
'disulphide enzyme-substrate cross-linking' strategy (Supplemen-
tary Fig. 10)30,34–36, which enabled us to obtain four structures of
JMJD5(Q275C).Mn.NOG.RPS6(A138C), JMJD5(N308C).Mn.
NOG.RCCD1, JMJD5(N308C).Mn.2OG.RCCD1 and JMJD5
(W414C).Mn.NOG.RCCD1 as cross-linked complexes (Com-
plexes 2–5, respectively). In these structures, clear electron density
was observed for the substrate backbones that enabled modelling
of residues other than the target arginine (RPS6 aa 137–138 and
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sidechain conformations for the target arginine residues corre-
sponding to 'productive' (A in Complex 1) and 'non-productive'
(B in Complex 1) orientations were observed in Complexes 3/4
and 2/5, respectively (Fig. 3). Comparisons of the substrate
complexes with those containing 2OG and of apo-JMJD5 imply
'induced fit' on substrate binding involving substantial conforma-
tional changes in two loops and multiple active site residues (see
below and Fig. 4).
We were unable to obtain a JMJD5 structure complexed with
the hydroxylated product, but did obtain a JMJD5.Mn.succinate
(decarboxylation product) complex structure; this structure
manifests substantial conformational changes relative to the
2OG/NOG complexes (with/without substrate) including in
DSBH residues, such as the Fe(II) binding residue D323 (Fig. 4e
and Supplementary Fig. 11).
The combined structural analyses identify mobile regions
involved in substrate binding/product release during JMJD5
catalysis, i.e., the β3–β4 loop, N-terminal to DSBH (aa 234–254),
and the DSBH βIV–βV loop (aa 342–381, Fig. 4b–f). Except in
the apo-JMJD5 structure, the βIV–βV loop, which is involved in
substrate binding in other JmjC-hydroxylases including FIH37
and ycfDs30 (Fig. 5), adopts a partial helical conformation in all
JMJD5 structures (Fig. 4b–e). However, in the apo-JMJD5
structure, part of the βIV–βV loop (aa 351–361) adopts a hairpin
conformation (Fig. 4f). By contrast, the conformations of the β3–
β4 loop (aa 241–248) vary in all JMJD5 complexes (Fig. 4b–f). In
the 2OG complex structures, part of β3–β4 loop is either
disordered24, or has an 'open' conformation relative to the
substrate bound form. In the substrate complexes, the β3–β4 loop
folds to enclose the target arginine region and active site. In the
succinate complex, part of the β3–β4 loop (aa 241–248) is
disordered, whereas in the apo-JMJD5 structure the β3–β4 loop,
together with βIV–βV loop, encloses the active site entirely
(Fig. 4). Thus, the combined structural analyses reveal that the
β3–β4 and βIV–βV loops likely have a 'gating' role to facilitate
substrate binding and product release during catalysis.
Discussion
The finding that the transcription machinery is extensively
regulated by 2OG-oxygenases, including the HIF hydroxylases
and JmjC KDMs, raised the question as to whether they regulate
translation1,2. It is now clear that some 2OG-oxygenases (e.g., the
RIOX and RPS23 prolyl hydroxylases) catalyse PTMs to riboso-
mal (and associated regulatory) proteins and tRNA1,2. However,
only in a few cases have the 2OG-oxygenases been shown to be
crucial in animal biology; JMJD5 is one such enzyme and is
involved in the regulation of cell growth/division processes that
are inherently linked to translational capacity14,15,17,38.
Building from an extensive peptide-based screen for potential
JMJD5 substrates, our results provide evidence that JMJD5 is a
JmjC-hydroxylase, catalysing the stereoselective C-3 hydroxyla-
tion of arginyl residues in sequences from proteins involved in
chromatin stability (RCCD1) and translation (RPS6). In support
of this assignment of the catalytic role of JMJD5, comparisons of
JMJD5 structures with those of other 2OG-oxygenases reveal that
the overall JMJD5 fold is more similar to the JmjC-hydroxylases
than the KDMs, as is its substrate binding both in terms of the
relationship of the substrate arginyl-residue relative to the active
site Fe(II) and more general features (Figs. 5 and 6).
The most similar human JmjC-hydroxylases to JMJD5 are (in
order of decreasing similarity): the tRNA hydroxylase TYW5
(PDB: 3AL539, Cα RMSD= 1.9, Z= 26.2), JMJD7 (PDB: 4QU2,
Cα RMSD= 1.9, Z= 25.3;), the asparaginyl hydroxylase FIH
(PDB: 1H2K37, Cα RMSD= 2.2, Z= 24.4), and the lysyl hydro-
xylase JMJD6 (PDB: 3K2O40, Cα RMSD= 2.8, Z= 21.3). JMJD5
is more distantly related, at least in terms of overall structure, to
the prokaryotic arginyl-hydroxylases, ycfDEC (PDB: 4LIT30, Cα
RMSD= 3.1, Z= 15.9) and ycfDRM (PDB: 4CUG30, Cα RMSD=
3.5, Z= 15.7) (from Escherichiacoli and Rhodothermus marinus,
respectively), with which it shares a common biochemical func-
tion, i.e., (2S,3R)-arginyl-hydroxylation, and which likely reflect
evolutionary precursors of JMJD5 and other animal JmjC
enzymes30,32.
A unique feature of substrate binding at the JMJD5 active site
among the JmjC enzymes analysed concerns the crystallographic
observation of two conformations for the substrate arginine
sidechain—one apparently productive and one not (Fig. 3). The
productive conformation was observed for both RPS6 (Complex
1/A) and RCCD1 (Complexes 3 and 4) and is analogous to other
JmjC enzyme-substrate complexes, notably for FIH37 and
ycfDRM30. Interestingly, although JMJD5 and ycfDRM bind their
respective substrates with different N/C-directionality through the
active site channel, the general binding mode of the target Arg is
similar in the productive conformation. For both the bacterial
and human arginyl hydroxylases, the target arginine residues are
bound in hydrophobic pockets defined by Y243JMJD5 and
W310JMJD5 (Y137ycfD and M120ycfD) and are positioned to form
hydrogen-bonds to E238JMJD5 and S318JMJD5 (D118ycfD and
S208ycfD) (Figs. 6a, f). The non-productive conformation as
observed for both RPS6 and RCCD1 in JMJD5 Complexes 1/B, 2
and 5 (but not in ycfD or FIH) may reflect a substrate entry/
product release route, though a role in binding one of the other
arginine residues present in the substrate sequence at some stage
in catalysis cannot be ruled out.
Comparison of JMJD5 with the available substrate structures
for other JmjC-hydroxylases (i.e., FIH and ycfDRM/RIOX) is
interesting from catalytic and evolutionary perspectives (Fig. 6).
Although JMJD5 and FIH catalyse C-3 hydroxylations of differ-
ent residues with different stereoselectivities (i.e., 2S,3R vs. 2S,3S),
the positioning of hydroxylated methylenes relative to the metal is
strikingly similar, i.e., they nearly superimpose in overlaid
structures (Fig. 6e and 6f), demonstrating that the reactive oxi-
dising intermediates (FeIV=O) react from similar coordination
positions in both FIH and JMJD5. By contrast, although JMJD5
and prokaryotic ycfD both catalyse C-3 hydroxylations of
Fig. 4 Conformational changes observed in complexes representing steps in JMJD5 catalysis. a Proposed mechanism of JMJD5-catalysed (3R)-Arg-
hydroxylation (reactive intermediates in parentheses), b JMJD5.Mn.2OG, c JMJD5.Mn.NOG.RCCD1(139-142) (Complex 3), d JMJD5.Mn.succinate.RCCD1
(2S,3R-OH) (product) modelled complex, e JMJD5.Mn.succinate and f apo-JMJD5. The figure illustrates global and local changes occurring on substrate/
cosubstrate binding and product release, which is a characteristic feature of JMJD5 catalysis. Two mobile regions are involved in JMJD5 catalysis: (i) the
β3–β4 loop (N-terminal to the DSBH, aa 234–254, raspberry to cream), and (ii) the DSBH βIV–βV loop (aa 342–381, different blue shades). Analogous
loops are often involved in substrate binding by other JmjC-hydroxylases and KDMs, including FIH37, RIOX30, KDM4A57,58 and PHF859. The β3-β4 loop,
which is often relatively short as in some KDMs, is 'open' in the JMJD5.Mn.2OG-, 'partly open' in the substrate-, and disordered in the succinate-
complexes. In all JMJD5 structures, except for apo-JMJD5, the βIV–βV loop adopts a similar conformation (i.e., partly helical); however, in the apo
structure, part of βIV–βV loop (aa 351–361) adopts a hairpin conformation. Note the conformational changes in the sidechains of active site residues
involved in catalysis. The JMJD5.Mn.succinate.RCCD1(2S,3R-OH) complex was modelled using the JMJD5(N308C).RCCD1 (Complex 3) and JMJD5.
succinate structures as templates
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Fig. 5 Relationship of JMJD5 structure/topology with those of homologous JmjC-hydroxylases and JmjC KDMs. a–f Ribbon representations of JMJD5.Mn.
NOG.RCCD1(139–142) (PDB: 6F4R) (a), TYW5.Ni (PDB: 3AL5) (b), FIH.Fe.NOG.HIF-1α (786–826) (PDB: 1H2K) (c), ycfDRM.Mn.NOG.L16(72–91) (PDB:
4CUG) (d), PHF8.Fe.NOG.H3K4me3K9me2(2–25) (PDB: 3KV4) (e) and KDM4A.Ni.NOG.H3K9me2(7–14) (PDB: 2OX0) (f). Middle panels show
topologies as indicated, with DSBH core elements (βI–βVIII) in green, helices in cyan, additional β-strands in red, random coils in black, and the insert
between the fourth and fifth DSBH β-strands in blue. JMJD5 catalysis involves substantial conformational changes in the β3–β4 and βIV–V loop regions
(loops analogous to JMJD5 β3–β4 loop are labelled 'β3–β4 loop' in other JmjC-oxygenases); such movements have not been observed around the JmjC
KDM active sites on Nε-methylated lysine binding. In addition, JMJD5 lacks (i) the extended flexible loop region, immediately N-terminal to βI (yellow),
which is involved in binding Nε-methylated lysines (Kmen) and (ii) the chromatin- and Zn-binding domains present in most JmjC KDMs (note, structures of
PHF8 and KDM4A are only of catalytic domains). Thus, the overall JMJD5 fold together with its unique substrate binding features supports its assignment
as a JmjC-hydroxylase and not a KDM
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arginine residues with the same stereoselectivity (i.e., 2S, 3R), the
positioning of hydroxylated methylenes differs substantially
(Fig. 6a, f). Thus, the observed mode of JMJD5 hydroxylation
likely evolved away from that of the RIOX, both by altering the
coordination position from which the ferryl-oxo reacts and by
altering the directionality of substrate binding through the active
site.
Recent studies have proposed aminopeptidase activity for
JMJD5 on histone tails containing methylated arginines26 or Nε-
monomethyl-lysines27. While all of our 'productive' complexes
(1/A, 3 and 4) are consistent with those reported for other JmjC-
hydroxylases in terms of the relationship between the active site
metal and the oxidised C–H bond41,42, neither the 'productive'
nor the 'non-productive' complex structures (Fig. 3) appear to be
consistent with stereoselectively favoured efficient metal-based
backbone hydrolysis reactions. Thus, although there is precedent
for 2OG -oxygenases being part of multi-function proteins and
for the presence of the DSBH in hydrolytic enzymes42, our evi-
dence is that JMJD5 is a hydroxylase rather than a hydrolase; we
observed no clear evidence for JMJD5-catalysed hydrolysis of the
peptides we tested (within limits of detection). Thus, it is possible
that the reported histone aminopeptidase activity of JMJD526,27
requires factors other than the catalytic domain.
Although initially reported as a KDM11, JMJD5 lacks the
extended flexible loop region, immediately N-terminal to βI,
which folds into the active site and which is involved in binding
Nε-methylated lysine residues in most, but not all, JmjC KDMs1
(Fig. 5). In addition, JMJD5 catalysis involves substantial active-
site rearrangements and conformational changes in loop regions
(Fig. 4); such movements have not been observed around the
JmjC KDM active sites on Nε-methylated lysine binding but do
occur, at least with some, JmjC-hydroxylases30 (Fig. 5). These
structural features, together with the striking similarity in the
geometric positioning of hydroxylated C-3 hydrogens between
JMJD5 and FIH (Fig. 6e, f), and the lack of characteristic chro-
matin- and Zn-binding domains (present in most JmjC KDMs,
Fig. 5), support our assigned hydroxylase, rather than KDM
activity for JMJD51.
The biological significance of JMJD5-catalysed arginyl-hydro-
xylation remains to be established. We have not yet been able to
demonstrate cellular arginyl-hydroxylation of RPS6 or RCCD1 by
endogenous JMJD5, in the former case because of the difficulties
in observing sufficiently high quality proteomic coverage in the
relevant region due to the abundance of charged residues in the
vicinity of the target R137. In the case of RCCD1, we did not
observe Arg-hydroxylation on the immuno-purified Myc-tagged
RCCD1 from 293 T cells by proteomic analyses, possibly because
RCCD1 is a relatively poor substrate for JMJD5 (Supplementary
Fig. 8), or because hydroxylated RCCD1 undergoes rapid
degradation. Our cellular results with JMJD5 contrast with those
for ycfD, where we were able to obtain high quality MS results
both for the intact ribosomal protein L16 and after proteolytic
digestion31, demonstrating C-3 arginyl-hydroxylation does not
preclude MS analyses. However, L16 is a relatively tractable
protein compared to RCCD1 and RPS6; RCCD1 associates with
chromatin (and with JMJD5)20 and RPS6 is subject to multiple











































































































































































































Fig. 6 Comparison of the active site substrate binding modes for JMJD5
and related JmjC enzymes. Red/blue arrows indicate hydroxylation/
demethylation sites, respectively. Active-site metals (Fe or Fe surrogates,
Mn/Ni) are colour-coded spheres. Values represent distances (Å) from the
metal to the oxidised carbon. a ycfDRM.Mn.NOG.L16(72–91) (PDB: 4CUG),
b NO66.Mn.NOG.RPL8(205–224) (PDB: 4CCO), c PHF8.Fe.NOG.
H3K4me3K9me2(2–25) (PDB: 3KV4), d KDM4A.Ni.NOG.H3K9me2(7–14)
(PDB: 2OX0), e FIH.Fe.NOG.HIF-1α (786–826) (PDB: 1H2K), f JMJD5.Mn.
NOG.RCCD1(139–142) (PDB: 6F4R). Note variations in the N- to C-
substrate directionality in the active site cleft (indicated by black arrows),
and variations in the hydroxylation site relative to the metal (boxed).
JMJD5 binds substrates (f) with the same substrate N/C-directionality, as
for most KDMs (KDM4A, KDM6B and KDM6A, d), but differing from that
for RIOX (a, b) and for one KDM, PHF8 (and likely other KDM2/
7 subfamily members, c). Overall, the mode of JMJD5-catalysed
hydroxylation more closely resembles that of FIH (e) compared to other
JmjC-hydroxylases and KDMs, consistent with the proposal that the FIH/
JMJD5 subgroup of JmjC-hydroxylases evolved from prokaryotic RIOX
including by loss of the 'Winged helix' (WH) domains, which are located at
the C-terminus of all RIOX30,32
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even when using synthetic peptides, our MS/MS data for arginyl
C-3 hydroxylation was not unequivocal (Fig. 1b) and required
analyses by NMR and, following hydrolysis, by amino acid ana-
lysis and comparison with synthetic standards, for confident
assignment of arginyl C-3 hydroxylation. Thus, the results imply
a gap in the capability of current proteomics methodology and
reaffirm the importance of comparison with synthetic standards
for the assignment of new PTMs.
The evidence for human Arg-hydroxylation is notable as it
defines a new type of mammalian enzyme-catalysed PTM that
links the JmjC-hydroxylases and KDMs. Future work can focus
on the role of JMJD5-catalysed Arg-hydroxylation in the reg-
ulation of translation and ribosome stability/function, where
RPS6 has essential roles. JMJD5-catalysed RCCD1 Arg-
hydroxylation may have a role in chromosome segregation as
both JMJD5 and RCCD1 are required for the maintenance of
chromosomal stability/fidelity during cell division20. Consistent
with its role in cell proliferation, JMJD5 is substantially upregu-
lated in cancers and leukaemia and consequently is a potential
cancer target22,23,45. The unusual 2OG and substrate binding
modes adopted by JMJD5 suggest that it should be possible both
to identify selective inhibitors for JMJD5 and to avoid JMJD5
when targeting other human 2OG-oxygenases; the latter is
important because inhibitors for human 2OG-oxygenases are in
clinical trials for diseases including anaemia46 and cancer9.
Methods
Materials. Chemicals were from Sigma-Aldrich, Merck Chemicals or Alfa Aesar.
Matrix-assisted laser desorption/ionisation time-of-flight (MALDI-TOF) matrices,
matrix buffers and calibrants were from LaserBio Labs (Valbonne, France). RCCD1
(139CARAY143) and the RPS6 (129VPRRLGPKRASRIRKL144) peptide substrates
(C-terminal amides) were either synthesised in-house (see below) or from G.L.
Biochem (Shanghai, China). DNA primers were from Sigma Genosys.
Expression and purification. DNA encoding for full-length JMJD5
(GI:223942014) was inserted into the pNIC28-Bsa4 vector (GenBank ID:
EF198106) for expression in E. coli (ATCC 25922) with an N-terminal His6 tag. N-
terminally truncated JMJD5 (aa 183–416) and (aa 153–416) constructs were gen-
erated by PCR from the full-length construct and inserted into pNIC28-Bsa4 and
pNH-TrxT, respectively. JMJD5 variants were prepared using site-directed muta-
genesis (New England Biolabs). Primer sequences are shown in Supplementary
Table 2. All constructs were verified by DNA sequencing. Wild type and variant
JMJD5 proteins were produced in E. coli Rosetta2 (DE3)-pLysS cells by induction
with 0.5 mM isopropyl β-D-1-thiogalactopyranoside for 16–18 h at 18 °C (180
rpm). Cells were freeze-thawed and resuspended in 50 mM HEPES-Na pH 7.5, 500
mM NaCl, 20 mM imidazole (supplemented with an EDTA-free protease inhibitor
cocktail tablet/Roche and bovine pancreatic grade II DNaseI/Roche) and lysed by
ultra-sonication. Proteins were purified by Ni2+-affinity (5 mL HisTrap, GE
Healthcare) chromatography followed by size-exclusion chromatography (50 mM
HEPES-Na pH 7.5, 100–200 mM NaCl and 5% glycerol) and/or buffer-exchanged
into storage buffer (50 mM HEPES-Na pH 7.5, 100–200 mM NaCl and 5% gly-
cerol) using a 30 kDa MWCO filter (Amicon). KDM4A/JMJD2A (aa 1–359/
pNIC28-Bsa4) and ycfD (aa 1–373/pET-28a) were produced as described29,30.
Protein purity was assessed by SDS-PAGE and masses of the purified proteins were
verified by LC-MS using a Merck Chromolith C18 2 × 5 mm guard column coupled
to a Waters LCT Premier XE, equipped with an electrospray interface.
Peptide synthesis. All peptides in this study (except as described in the Materials
section), including those in the ribosomal peptide library (Supplementary Data 1),
were prepared by standard solid-phase synthesis using an Intavis Multipep auto-
mated peptide synthesiser with Tentagel-S-RAM resin (Rapp-Polymere) and N,N
′-diisopropylcarbodiimide (DIC) as a coupling reagent. Final cleavage using 2.5%
triisopropylsilane in CF3COOH yielded the peptides as C-terminal amides, which
were precipitated in cold ether, redissolved in MilliQ water and then freeze-dried.
The masses of peptide products were verified using MALDI-TOF mass spectro-
metry as described below.
Endpoint assays. The hydroxylase/demethylase activityies of JMJD5 and JMJD2A
on peptides was assessed using a MALDI-MS-based assay. Reactions consisted of
enzyme (1–10 μM), (NH4)2Fe(SO4)2 (100 μM), sodium-(+)-L-ascorbate (500 μM),
2OG-disodium (200 μM) and peptide (10–50 μM) in 50 mM HEPES pH 7.5, 50
mM NaCl. Solutions of cofactors (ascorbate, 2OG and FeII) were prepared
immediately prior to use at 20× the desired final concentration; ascorbate and 2OG
were dissolved in 50 mM HEPES pH 7.5 and (NH4)2Fe(SO4)2 was prepared as a
100 mM solution in 20 mM HCl and diluted further with MilliQ water. Reactions
were prepared by the addition of buffer and 2OG, followed by ascorbate, iron,
enzyme and finally peptide, and were incubated at room temperature, or at 37 °C,
for the indicated times before being quenched with 0.1% formate.
To assess product formation, 1 µL of quenched hydroxylation/demethylation
reaction was mixed with 1 μL of α-cyano-4-hydroxycinnamic acid (CHCA) matrix (10
mgmL−1 in 50% acetonitrile, 50% MilliQ water with 0.1% trifluoroacetic acid) and
spotted onto a MALDI plate for analysis using a MALDI micro-MX mass spectrometer
(Waters, USA) in reflectron-positive ion mode: pulse voltage 1250V, detector voltage
2750V, mass suppression 1000Da. Data were analysed using MassLynx 4.0.
Kinetic analyses. For kinetic measurements, hydroxylation activity was tested using
a mixture of (final concentrations) 10 µM JMJD5, 100 µM Fe(NH4)2(SO4)2 and 400
µM sodium-(+)-L-ascorbate in 50mM HEPES-Na pH 7.5. Reaction was initiated by
adding a mixture of 100 µM RPS6129–144 peptide (VPRRLGPKRASRIRKL) and 500
µM 2OG-disodium salt solution. Reactions were carried out in V-bottom 96-well
plates (Microlate, Grenier, Germany) on a mixer (Thermomixer C, Eppendorf) at 37
°C and quenched by addition of 1% formate. The extent of hydroxylation was
examined by MALDI-TOF using CHCA as the matrix34. For the determination of
the apparent Km values, MALDI-MS-based assays were carried out over a range of Fe
(3–150 µM)/2OG (3–150 µM)/RPS6129–144 (3–300 µM) concentrations. The initial
reaction rates (ν0) for each concentration point were plotted against the corre-
sponding Fe/2OG/RPS6 concentration using GraphPad Prism version 5.0 (GraphPad
Software, San Diego, CA, USA) and the kinetic parameters (Km and kcat) were
determined based on the Michaelis–Menten equation.
NMR analyses. To generate hydroxylated-RPS6129–144 peptide for NMR analysis, a
large-scale (5 mL) reaction was prepared with 210 µM RPS6129–144 peptide (~2 mg
total), 40 µM His6-JMJD5, 1 mM ascorbate, 400 µM (NH4)2Fe(SO4)2 and 400 µM
2OG. The reaction was incubated at room temperature and product formation
monitored at 10-min intervals by MALDI-TOF MS. After 1 h, 100% of the peptide
had been converted to the hydroxylated product. Hydroxy-RPS6 was purified by
gel filtration using a Superdex Peptide 10/300 GL column (GE Healthcare) in 200
mM ammonium bicarbonate, then desalted using a Sep-Pak C18 cartridge (Waters,
USA). The purified peptide was freeze dried and stored at −20 °C.
Cofactors were prepared as described above in 20 mM Tris pH 7.5.
Recombinant His6-JMJD5 proteins (wild type and H321A variant) were buffer
exchanged into 20 mM Tris pH 7.5 using Micro Bio-Spin Chromatography
Columns (Bio-Rad). One hundred sixty-microlitre reactions were prepared in a 1.5
mL Eppendorf tube with 16 µL D2O, 100 µM (NH4)2Fe(SO4)2, 200 µM 2OG, ±500
µM ascorbate, ±1 mM NOG and ±10 µM His6-JMJD5 (wild type/H321A) in 20
mM Tris D11 (Cambridge Isotope Laboratories), pH 7.5. Reactions were initiated
by the addition of enzyme and immediately transferred to a 3 mm Shigemi NMR
tube, which was centrifuged for a few seconds in a hand centrifuge. Proton NMR
spectra were acquired, and the reaction was monitored in real time using a Bruker
Avance III 700MHz spectrometer equipped with a 5 mm inverse TCI cryoprobe at
298 K. The AV700 was controlled by TopSpin software; spectrometer conditions
were optimised using a control sample with all reaction components except enzyme
prior to data acquisition. The first proton spectrum was acquired with water
suppression, 325 s after mixing, following brief optimisation (start of data
acquisition was 225 s). Spectra were automatically acquired every 105 s for 1900 s.
TopSpin software was used to process and integrate the peaks corresponding to
2OG and succinate for analysis using Microsoft Excel.
Structure determination of the hydroxylated product was carried out on a
sample containing the hydroxylated peptide in D2O by NMR, using a Bruker
Avance AVIII 700MHz NMR spectrometer equipped with an inverse TCI
cryoprobe, optimised for 1H observation, and installed with Topspin software. The
D2O deuterium signal was used as an internal lock signal and 1H chemical shifts
are reported relative to the solvent (δH 4.7 ppm). Phase-sensitive HSQC and
magnitude-mode COSY spectra used pulsed field gradients and phase-sensitive
TOCSY experiments used the MLEV-17 mixing scheme (mixing times= 120 ms).
Amino-acid analyses. For the amino-acid analysis, 6-aminoquinolyl-N-hydro-
xysuccinimidyl carbamate (AQC) was synthesised following the procedure of
Cohen and Michaud47. Di-(N-succinimidyl) carbonate (DSC) (0.213 g; 0.832
mmol; 1.2 eq.) was dissolved in dry acetonitrile (7 mL) under a N2 atm, and heated
to reflux. 6-Aminoquinoline (0.107 g; 0.694 mmol; 1 eq.) dissolved in dry acet-
onitrile (3 mL) was added dropwise to the refluxing solution over 30 min. The
solution was refluxed for another 30 min, during which formation of a yellow
precipitate was observed. The solution was then allowed to cool to room tem-
perature and the yellow precipitate was filtered off before concentrating to half
volume, and cooling to 4 °C overnight to allow the product to precipitate. The
resulting white crystals were collected by filtration, and washed with cold acet-
onitrile. The product was recrystallised from acetonitrile (52% yield) and char-
acterised by comparison of its NMR data and melting point with those reported47.
Hydroxylated RPS6129–144 peptide for amino-acid analysis was prepared as
described48. Dried reaction mixtures (containing ~20 µg of hydroxylated peptide)
were reconstituted in MilliQ water and enzymatic hydrolysis was carried out for 16
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h at 37 °C using protease from Streptomyces griseus at a 1:5 protease-to-peptide
ratio. Hydrolysates were dried by vacuum centrifugation, reconstituted in 80 µL of
0.2 M borate buffer pH 9.0 and derivatised by the addition of 20 µL AQC.
Hydroxyarginine standards used to assign stereochemistry (2S,3R-Arg(OH)•2HCl
and 2S,3S-Arg(OH)•2HCl) were kind gifts from Christian Ducho, Georg-August-
University Göttingen49.
Mass spectrometric analyses. LC-MS analyses of derivatised amino-acid stan-
dards and hydrolysates were performed as described50 using a Waters Acquity ultra
performance liquid chromatography system coupled to an LCT Premier XE
orthogonal acceleration time-of-flight mass spectrometer equipped with an elec-
trospray ionisation source (Waters, USA). Derivatised amino acids were separated
using an increasing gradient of Solvent B (1.3% (v/v) formic acid in acetonitrile) in
Solvent A (AccQ Tag Ultra Phase A), at a flow rate of 0.7 mLmin−1. The condi-
tions for ESI-MS detection were as follows: positive-ion mode, V-mode analyser,
desolvation temperature at 250 °C, source temperature at 120 °C, capillary voltage
at 3000 V, sample cone voltage at 100 V, cone and desolvation gas flow at 30 and
550 Lmin−1, respectively. The MS data were acquired and an extracted ion
chromatogram produced for m/z 361, corresponding to singly derivatised hydro-
xyarginine. Data were analysed using MassLynx 4.1.
For tandem MS analyses, samples were directly mixed onto the MALDI target
plate using 0.8 µL of 10 mgmL−1 CHCA in 50% (v/v) acetonitrile with 0.1% (v/v)
formic acid and air-dried. Tandem MS was performed using a MALDI-TOF/TOF
4800 plus mass spectrometer (Applied Biosystems). Each reflectron MS spectrum
was collected in an independent acquisition positive mode, typically using 1000
laser shots per spectra and a fixed laser intensity of 2900 V. The strongest
precursors were selected for MS/MS, and the analyses were performed using
Collision Induced Dissociation (CID) assisted with air, with a collision energy of 1
kV and gas pressure of 1 × 106 torr. Two thousand laser shots were collected for
each MS/MS spectrum using a fixed laser intensity of 4500 V. Raw data analysis
was performed with Data Explorer 2.1 software from Applied Biosystems. The
mass corresponding to x and x+ 16, equivalent to one hydroxylation, were
identified and MS/MS spectra were annotated manually.
Crystallography. Crystals of N-terminally truncated JMJD5 (aa 153–416 and aa
183–416) wt/variant complexes (0.8mM His6-JMJD5, 1.5 mM MnCl2, 2.5mM 2OG/
NOG (or 50mM succinate) and 10mM substrate) were grown by vapour diffusion at
22 °C in 300 nL sitting drops in 2:1 or 1:1 or 1:2 ratio of sample to well solution (0.1
M Bis-Tris pH 5.8–6.5, 15–32% w/v polyethylene glycol 3350, 2 mM MnCl2). In
general, crystals were cryoprotected by transferring to a solution of mother liquor
supplemented with 25% (v/v) glycerol before being cyro-cooled in liquid N2. Data
were collected at 100 K using synchrotron radiation at the Diamond Light Source
(DLS) beamline I03 (0.9795 Å) equipped with a Dectris Pilatus3 6M detector. Data
were processed as outlined in the Supplementary Tables 4 and 5. Structures were
solved by molecular replacement using PHASER51 (search model PDB ID 4GJZ)24
and refined by alternative cycles of PHENIX52, CNS53 and BUSTER54 using the
maximum-likelihood function and bulk-solvent modelling. Iterative cycles of model
building in COOT55 and refinement proceeded until the R/Rfree values converged.
Final rounds of refinement were performed by PHENIX52. MOLPROBITY56 was
used to monitor the geometric quality of the models between refinement cycles and
identify poorly modelled areas needing attention. Water molecules were added to
peaks >1.5σ in 2Fo−Fc electron density maps that were within hydrogen bonding
distance to protein residues with reasonable hydrogen bonding geometry. Data
collection and refinement statistics are shown in the Supplementary Tables 4 and 5.
Statistical analysis. Endpoint assay results are the mean of three independent
experiments with error bars representing the s.e.m. For kinetic measurements, each
experiment was carried out (at least) in triplicate (n= 3–9).
Data availability. GenBank accession codes for the sequences mentioned in this
article are as follows: Q8N371 (KDM8_HUMAN); P62753 (RS6_HUMAN);
A6NED2 (RCCD1_HUMAN). Atomic coordinates and structure factors for the
crystal structures of JMJD5-apo (PDB: 6F4M), JMJD5.2OG (PDB: 6F4N), JMJD5.
succinate (PDB: 6F4O), Complexes 1 (PDB: 6F4P), 2 (PDB: 6F4Q), 3 (PDB: 6F4R),
4 (PDB: 6F4S), and 5 (PDB: 6F4T) are deposited in the protein databank (wwPDB).
Additional data supporting the findings of this study are available from the cor-
responding authors on reasonable request.
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